Blog
RSS FeedPosted by Michael Wonder on 10 Mar 2020
Decision to fund betamethasone dipropionate with calcipotriol (Enstilar) foam spray for psoriasis
10 March 2020 - PHARMAC is pleased to announce the approval of a decision to fund a new topical psoriasis ...
Posted by Michael Wonder on 15 Jan 2020
Proposal to fund betamethasone dipropionate with calcipotriol (Enstilar) foam spray for psoriasis
15 January 2020 - PHARMAC is seeking feedback on a proposal to fund a new topical psoriasis medicine, betamethasone dipropionate ...
Posted by Michael Wonder on 12 Dec 2019
Decision to award sole supply for fluticasone and fluticasone with salmeterol metered dose inhalers
12 December 2019 - PHARMAC has made a decision to make changes to the funded brands of fluticasone and fluticasone ...
Posted by Michael Wonder on 22 Aug 2019
PTAC continues to find new ways to reject new medicines (Part 2)
23 August 2019 - More startling insights from the minutes of the May 2019 PTAC meeting. ...
Posted by Michael Wonder on 31 Jan 2019
Relief as government funded hep C drugs become available
1 February 2019 - The "modern lepers" of the health system have come in from exile, hepatitis C campaigner Hazel ...
Posted by Michael Wonder on 31 Jan 2019
New Zealand Pharmaceutical Schedule - 1 February 2019 update
1 February 2019 - The February 2019 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 17 Dec 2018
PHARMAC funding decision gives Kiwis with hepatitis C access to a potential cure
17 December 2018 - Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February ...
Posted by Michael Wonder on 17 Dec 2018
Decision to fund a new hepatitis C treatment (Maviret) and to widen access to adalimumab (Humira) for psoriasis
17 December 2018 - PHARMAC is pleased to announce a decision to fund a new treatment for chronic hepatitis C ...
Posted by Michael Wonder on 24 Oct 2018
Further update on proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C
24 October 2018 - This is a further update on the proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis ...
Posted by Michael Wonder on 01 Oct 2018
PHARMAC must fund breakthrough treatment
1 October 2018 - Cystic Fibrosis NZ and Kalydeco for Kiwis have launched a joint campaign urging PHARMAC to fund ...
Posted by Michael Wonder on 29 Sep 2018
New Zealand Pharmaceutical Schedule - 1 October 2018 update
1 October 2018 - The October 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 27 Aug 2018
Update on proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)
27 August 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to fund glecaprevir and ...
Posted by Michael Wonder on 01 Aug 2018
Free access plan for 'revolutionary' drug that could eliminate Hepatitis C by 2030
1 August 2018 - What has been called a "revolutionary" hepatitis C drug could soon be available free-of-charge to all ...
Posted by Michael Wonder on 20 Jul 2018
Proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)
20 July 2018 - PHARMAC is seeking feedback on a proposal to fund a pangenotypic treatment for chronic hepatitis C ...
Posted by Michael Wonder on 07 Feb 2018
No political pressure in HIV drug funding call - PHARMAC
7 February 2018 - PHARMAC is rejecting any suggestion it reacted to political pressure to fund a new anti-HIV drug. ...